HCPCS Code J2320: Nandrolone decanoate billing guide 2026

Key takeaways

HCPCS Code J2320 describes the injection of nandrolone decanoate, up to 50 mg. The code is active for 2026 with no termination date on record.

Medicare Part B reimburses J2320 under the Average Sales Price plus 6% methodology, with rates set by MAC locality and updated quarterly.

Every claim must pair J2320 with a supported ICD-10-CM diagnosis code, and the chart must record the order, dose, route, and diagnosis linkage.

The drug and its administration are billed separately, so J2320 travels with an injection code such as 96372.

Practice management software like Pabau ties J-code billing to the clinical record, so dose, diagnosis, and NDC are captured at the point of care.

HCPCS Code J2320 is the billing code for an injection of nandrolone decanoate, up to 50 mg. It belongs to the HCPCS Level II J-code set, maintained by the Centers for Medicare and Medicaid Services (CMS).

That set covers injectable drugs a patient cannot self-administer. The code is active for 2026 with no termination date on record.

Three things make J2320 harder to bill than a standard office visit.

• The payment rate changes every quarter, so last quarter’s fee schedule is already stale.
• Coverage is set locally by each Medicare Administrative Contractor (MAC), not nationally.
• Nandrolone decanoate is a controlled substance, so the record has to satisfy DEA rules as well as the payer.

Because nandrolone decanoate is a DEA Schedule III controlled substance, dispensing and administration carry documentation duties beyond standard drug billing. The record needs more than a billing code. Document the controlled substance order, the dose drawn and administered, and the credentials of the clinician who gave it.

Clinical indications and medical necessity

Medicare covers J2320 for anemia associated with renal insufficiency, including anemia of chronic renal failure. That is the most consistently covered use across MAC jurisdictions.

Nandrolone decanoate is an anabolic androgenic steroid, and its approved uses are narrow. Practices treating end-stage renal disease or anemia from chronic kidney disease should pair J2320 with a code from the N18 or D63 categories.

Coverage for other indications, including osteoporosis in postmenopausal women, varies by MAC and depends on Local Coverage Determination (LCD) policy. Before billing J2320 for anything outside anemia of renal failure, pull the LCD for your jurisdiction. Some MACs have written narrower policies than others.

• Covered (primary): Anemia associated with renal insufficiency, including anemia of chronic renal failure
• Varies by MAC LCD: Osteoporosis in certain clinical scenarios and metastatic breast cancer, so verify the current LCD
• Not billable to Part B: Off-label anabolic or performance use, which Medicare does not cover at all

Off-label requests are therefore a self-pay conversation. Price and consent them before the injection rather than billing afterward.

Medical necessity has to be documented, not implied. The chart must establish the diagnosis, give the clinical reason for injectable nandrolone decanoate, and link the drug administered to the billed code. A diagnosis code on its own will not carry the claim.

J2320 Medicare reimbursement and the 2026 fee schedule

Medicare Part B reimburses HCPCS Code J2320 under the Average Sales Price plus 6% (ASP+6%) methodology. CMS updates ASP payment allowances quarterly. The rate for January through March 2026 may differ from the rate applied in October through December.

Verify the current allowance against the CMS fee schedule tool before you submit.

Under ASP+6%, the allowed amount is the manufacturer’s average sales price as reported to CMS. The 6% add-on covers handling and administration overhead. Rates vary by MAC locality, so two practices submitting the identical claim in different regions can be paid different amounts.

J2320 pays for the drug only. The injection itself is billed separately, usually with 96372 for a therapeutic intramuscular injection. Leaving that line off the claim means the practice absorbs the administration work for free.

Commercial rates for J2320 are not standardized. Some plans benchmark against Medicare’s ASP-based rate, and others pay a contracted amount that can be higher or lower. Check the allowance before the drug is administered.

The buy-and-bill spread, meaning the difference between acquisition cost and reimbursement, decides whether each administration pays for itself. On a thin spread, one unverified allowance can wipe out the margin on a whole treatment course.

Medicare coverage and payer policy

Medicare Part B covers J2320 when a physician administers the drug in a covered setting and the diagnosis establishes medical necessity. Coverage sits under National Coverage Determinations (NCDs) and, more often for J-codes, the LCD issued by your MAC.

No national NCD governs nandrolone decanoate. Coverage is decided locally, so practices in different MAC regions can face different requirements for the same code. Pull the applicable LCD before billing and confirm the patient’s diagnosis is listed as covered.

Prior authorization is another local variable. Medicare Part B does not require it for most physician-administered drugs, while commercial and Medicare Advantage plans differ. Practices running injectable drug workflows across several payers need a per-plan record of what each one demands.

Practice management software like Pabau keeps those rules on the payer record. Its claims management tools then flag any claim that needs authorization before submission.

ICD-10 crosswalk: Diagnosis codes that support J2320

Every J2320 claim needs an ICD-10-CM diagnosis code that justifies the injection. The table below lists the codes most often paired with the covered indications. Verify the crosswalk against your MAC’s current LCD before submitting, because covered diagnoses change.

Staging matters when you bill for anemia of chronic kidney disease. Sequence D63.1 alongside the appropriate N18 code so the claim shows both the anemia and the underlying renal condition.

ICD-10-CM guidelines call for coding the underlying condition when the anemia is a manifestation of it. That pairing is also what makes the medical necessity case readable to a reviewer.

NDC reporting and the J2320 crosswalk

Many payers want the National Drug Code (NDC) on the claim line next to the HCPCS code. The NDC identifies the exact product administered, down to manufacturer, formulation, and package size.

Requirements vary by payer. Medicaid programs require an NDC on most drug claims, and Medicare Part B usually does not ask for one on the Part B claim. State Medicaid and commercial plans increasingly do.

Nandrolone decanoate products in the US market have changed over time. The NDCs in circulation shift as formulations enter and leave the market. Use the CMS NDC-to-HCPCS crosswalk file, updated quarterly, to confirm that the product on your shelf still maps to J2320.

An outdated NDC is a common cause of drug claim rejections. AAPC’s HCPCS lookup carries crosswalk references that supplement the CMS file.

• NDC format on claims: 11-digit format required (5-4-2); convert from the 10-digit packaging NDC as needed
• Unit reporting: Report NDC units in the unit of measure on the NDC label (for example, ML), not HCPCS units
• Crosswalk verification: Use the current CMS NDC-to-HCPCS crosswalk file, updated quarterly
• Medicaid: NDC reporting is mandatory for most Medicaid drug claims, and a missing NDC means rejection

Linking the NDC at the point of dispensing, rather than at billing, cuts the risk of a mismatched code. Pabau’s prescription management records the exact product given, with lot and expiration, so the claim carries the same NDC as the vial.

Billing guidelines and modifiers

J2320 follows the standard rules for physician-administered Part B drugs, with a few specifics worth knowing.

Units of service

J2320 is defined as up to 50 mg, so one unit covers any dose to that limit. A dose above 50 mg is billed as additional units, which makes a 100 mg dose 2 units. Never bill a partial unit. Round up to the next whole unit when the dose exceeds the per-unit increment.

Unit definitions differ across HCPCS Level II, so read the descriptor before you calculate. Time-based codes such as G0152 bill in 15-minute blocks, while procedure codes such as 11043 bill by the area treated.

Place of service and revenue codes

J2320 given in a physician office is billed on a CMS-1500 form with place of service code 11. In an outpatient hospital setting the claim goes on a UB-04 form instead.

Use revenue code 0636 for drugs requiring detailed coding, or 0260 for IV solutions, depending on the facility’s chargemaster. Place of service affects the allowed amount under Medicare’s site-of-service differential, so it must match where the drug was given.

Applicable modifiers

Two modifiers come up for J2320. Report modifier JW when part of a single-dose vial is discarded after administration. Medicare wants that discarded amount on its own claim line so the payment is calculated correctly.

Modifier JZ attests that nothing was discarded. Check your MAC guidance and read the CMS discarded drug policy, because enforcement has tightened.

Documentation requirements for J2320

Documentation for J2320 does two jobs. It establishes medical necessity for the drug and it verifies the administration event. Auditors reviewing J-code claims look for both. A diagnosis with no administration record, or an administration note with no supporting diagnosis, will not survive review.

The elements below have to appear in the record. Digital intake forms can capture them at every encounter, so nothing is missing when a payer asks for the chart.

• Physician order: A signed order for nandrolone decanoate injection, specifying dose and route
• Diagnosis documentation: The covered ICD-10-CM diagnosis, with clinical narrative supporting medical necessity
• Administration record: Date, time, dose administered (in mg), route, site, and the name of the administering clinician
• Drug identification: The NDC of the product used, lot number, and expiration date
• Controlled substance log: Because nandrolone decanoate is DEA Schedule III, keep a dispensing log that meets DEA and state pharmacy board rules
• Monitoring note: Any follow-up observation the ordering clinician requires, particularly for ongoing anemia management

Medicare’s claims retention rules mean these records must still be reachable if a post-payment audit lands. HIPAA compliance governs how you store and share them. Records that link the administration note to the claim cut audit response time sharply.

How Pabau connects J-code documentation to the claim

The weak point in J-code billing is the handoff between the clinical encounter and the claim. A clinician administers nandrolone decanoate and documents it in the chart. Someone in billing then rebuilds that event as a claim line from the notes, checking dose, units, NDC, and diagnosis linkage.

Errors surface weeks later, when the denial arrives and the appeal starts. Practice management software that holds scheduling, documentation, and billing in one system removes the manual transfer step. The billing detail is captured while the drug is being given.

Pabau’s automated billing workflows connect the administration record to charge capture. When a clinician records an administration, Pabau prompts for dose, route, and diagnosis linkage, then pre-populates the claim with the code and units. That matters most in IV therapy practices, where J-code volume is high.

Reporting closes the loop. Pabau’s reporting and analytics, included in every subscription, tracks payments by procedure code. You can see where J2320 is underpaid and which payers are behind it. Comparing received payments against expected ASP-based rates tells you whether in-office administration still pays for itself.

The same visibility matters for any practice giving injections on a schedule. Men’s health practices and any group practice sharing one billing team run into the same per-unit and waste-reporting rules.

Capture J-code billing at the point of care

Pabau ties the administration record to the claim, so dose, diagnosis, and NDC arrive with the charge. That means fewer J-code denials and less rework for your billing team.

Book a demo

Conclusion

J2320 is easy to look up and easy to get wrong. The code itself stays fixed all year. The payment rate and the covered diagnosis list do not.

So build the checks into the workflow instead of the month-end review. When the diagnosis, dose, NDC, and waste line are captured as the drug is drawn, the claim leaves clean and the appeal never happens.

The practices that struggle with J-codes are the ones treating billing as a job that starts after treatment ends. Book a demo to see how Pabau captures J-code documentation and billing in one workflow.

Continue your research

Need to spell out medical necessity in writing? Medical necessity letter gives you a structure payers accept for a drug they are likely to question.

Billing another injectable by volume? J1460 shows how per-unit dosing changes the way a J-code claim is built.

Reporting waste from a single-dose vial? J9267 walks through per-milligram units and the discarded-amount rules that follow them.

Documenting an infusion or injection visit? IV therapy intake form captures the history and consent detail an audit of injectable care asks for.

Billing the same care outside the US? MBS item numbers explains how Australia’s schedule structures item claims and rebates.

Frequently asked questions